[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345253-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-345253-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","chemoresistance-in-gynecologic-cancers-mechanistic-insights-and-emerging-platforms-to-overcome-drug-failure","Chemoresistance in gynecologic cancers - mechanistic insights and emerging platforms to overcome drug failure","","Chemoresistance presents a major barrier to treating gynecologic cancers, particularly ovarian cancer, where frequent relapse and platinum resistance drive poor outcomes. This review synthesizes biological, molecular, and micro-environmental mechanisms underlying resistance, emphasizing ovarian cancer while comparing related cervical and endometrial malignancies. It covers drug efflux, redox detoxification, DNA repair, apoptosis evasion, tumor microenvironment protection, EMT, cancer stem cell persistence, epigenetic reprogramming, and exosome signaling, then summarizes emerging strategies and AI/multi-omics for predicting response and enabling personalized management.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/chemoresistance-in-gynecologic-cancers-mechanistic-insights-and-emerging-platforms-to-overcome-drug-failure/345253/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/chemoresistance-in-gynecologic-cancers-mechanistic-insights-and-emerging-platforms-to-overcome-drug-failure/345253.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"Why is chemoresistance a critical challenge in gynecologic cancers?","Question",{"text":63,"@type":64},"Chemoresistance makes cancer cells unresponsive to previously effective therapies, contributing to ongoing disease, reduced treatment effectiveness, and poorer survival outcomes. Ovarian cancer is especially challenging due to frequent relapse and platinum resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What are the two major types of chemoresistance discussed?",{"text":68,"@type":64},"Intrinsic (primary) resistance exists at the start of therapy when patients do not respond to first-line treatment. Acquired resistance develops during or after treatment, often after an initial period of responsiveness.",{"name":70,"@type":61,"acceptedAnswer":71},"Which mechanisms of chemoresistance does the review emphasize?",{"text":72,"@type":64},"Key mechanisms include increased drug efflux, redox-based detoxification, enhanced DNA repair, evasion of apoptosis, protection by the tumor microenvironment, epithelial-mesenchymal transition, persistence of cancer stem cells, epigenetic reprogramming, and exosome-based communication.",{"name":74,"@type":61,"acceptedAnswer":75},"How does the review propose overcoming drug failure, especially in platinum-resistant ovarian cancer?",{"text":76,"@type":64},"It highlights emerging approaches such as drug efflux transporter inhibitors, modulators of redox and metabolic pathways, DNA repair and epigenetic interventions, immunotherapies, tumor microenvironment strategies, nanotechnology delivery systems, and exosome-related interventions. It also discusses AI and multi-omics methods for predicting treatment response and enabling personalized care.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},345253,1790155995,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,109,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},"Technology",50,"technology",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},7,"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Garg et al. Journal of Ovarian Research (2026) 19:162 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-026-02115-9](https://doi.org/10.1186/s13048-026-02115-9)  \nREVIEW Open Access  \nChemoresistance in gynecologic cancers:  mechanistic insights and emerging platforms to overcome drug failure  \nPankaj Garg1, Ravi Salgia2 and Sharad S. Singhal2*  \nAbstract  \nThe most difficult hurdles associated with the treatment of gynecologic cancer (such as ovarian, cervical, and endometrial cancer) is chemoresistance, with ovarian cancer representing the most clinically challenging subtype due to frequent relapse and the development of platinum resistance. Although chemotherapy remains one of the most important approaches to the management of gynecologic cancer, a large portion of patients have a poor initial response or recurrence of the treatment-resistant disease, factors that influence the rate of survival. This review highlights the present understanding of biological, molecular, and micro-environmental mechanisms that cause chemoresistance in gynecologic cancers, with primary emphasis on ovarian cancer while drawing supportive comparisons with cervical and endometrial malignancies. Important mechanisms of chemoresistance like increased drug efflux, redox based detoxification, increased capability of repairing DNA, evading apoptosis, protection by tumor microenvironment, epithelial-mesenchymal transition, persistence of cancer stem cells, epigenetic reprogramming and exosome-based communication are discussed in an integrated and easily understandable style. In addition to the overview of these mechanisms, this review also brings out newer treatment approaches that may emerge to overcome drug failure, especially in platinum-resistant ovarian cancer. These approaches include drug efflux transporter inhibitors, redox and metabolic pathways modulators, DNA repair, epigenetics, immunotherapies, tumor microenvironment, nanotechnology-delivery systems, and exosome interventions. The development in artificial intelligence and multi-omics methods that can be used to predict treatment response and deliver personalized management are also discussed, highlighting their potential role in early identification of resistance and treatment stratification in ovarian cancer patients. Collectively, these insights may help to improve therapeutic decision-making, which could enhance chemotherapy responsiveness, and support durable clinical outcomes in ovarian and other gynecologic malignancies.  \nKeywords Chemoresistance, Gynecologic cancer, Drug resistance mechanisms, Tumor microenvironment, Targeted therapeutic strategies  \n*Correspondence: Sharad S. Singhal[ssinghal@coh.org](ssinghal@coh.org)  \n1Department of Chemistry, GLA University, NH-19, Mathura-Delhi Road, Mathura, Uttar Pradesh 281406, India  \n2Department of Medical Oncology and Therapeutic Research, Beckman Research Institute of City of Hope, 1500 E Duarte Road, Duarte, CA 91010, USA  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://","cbCaievEaisX6VX1","https://ap.wps.com/l/cbCaievEaisX6VX1","pdf",1943923,17,"English","# Introduction\n## Types of chemoresistance\n# Mechanistic drivers of resistance\n## Cellular and molecular mechanisms\n## Tumor microenvironment and communication\n# Emerging strategies to overcome drug failure\n## Targeted inhibitors and modulators\n## Immunotherapies, nanotechnology, and exosome-based interventions\n# Predicting response with AI and multi-omics\n## Early identification and treatment stratification","[{\"question\":\"Why is chemoresistance a critical challenge in gynecologic cancers?\",\"answer\":\"Chemoresistance makes cancer cells unresponsive to previously effective therapies, contributing to ongoing disease, reduced treatment effectiveness, and poorer survival outcomes. Ovarian cancer is especially challenging due to frequent relapse and platinum resistance.\"},{\"question\":\"What are the two major types of chemoresistance discussed?\",\"answer\":\"Intrinsic (primary) resistance exists at the start of therapy when patients do not respond to first-line treatment. Acquired resistance develops during or after treatment, often after an initial period of responsiveness.\"},{\"question\":\"Which mechanisms of chemoresistance does the review emphasize?\",\"answer\":\"Key mechanisms include increased drug efflux, redox-based detoxification, enhanced DNA repair, evasion of apoptosis, protection by the tumor microenvironment, epithelial-mesenchymal transition, persistence of cancer stem cells, epigenetic reprogramming, and exosome-based communication.\"},{\"question\":\"How does the review propose overcoming drug failure, especially in platinum-resistant ovarian cancer?\",\"answer\":\"It highlights emerging approaches such as drug efflux transporter inhibitors, modulators of redox and metabolic pathways, DNA repair and epigenetic interventions, immunotherapies, tumor microenvironment strategies, nanotechnology delivery systems, and exosome-related interventions. It also discusses AI and multi-omics methods for predicting treatment response and enabling personalized care.\"}]","Chemoresistance in gynecologic cancers - mechanistic insights and emerging platforms to overcome drug failure | PDF",1790056962,43,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2bd8f3992e9a0998f9fdc2c63c86e9d7.webp",983,1310,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19fecba18490073e03e56108a0dd431e.webp",982,1309,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e03434b5853d8b134a1a07bb1ce30b89.webp",981,1308,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5fcd8d28f6b86aeda2421b4d972ba700.webp",980,1306]